Does prior transurethral resection of prostate have a negative impact on the outcome of holmium laser enucleation of prostate? Results from a prospective comparative study

Usama Khater, Nicholas Anthony Smith, Jonathan E. Katz, Abhishek Bhat, Indranee Banerjee, Rashmi H. Shah, Hemendra N. Shah

Department of Urology, University of Miami, Miller School of Medicine, Miami, Florida, USA, 1Urolap Superspeciality Clinic and S. L. Raheja (Fortis Associate Hospital), Mumbai, Maharashtra, India

Abstract

Objectives: To prospectively evaluate safety and efficacy of holmium laser enucleation of prostate (HoLEP) for surgical treatment of recurrent symptoms due to prostatomegaly after prior transurethral resection of prostate (TURP).

Materials and Methods: We prospectively evaluated 43 patients with a history of TURP who underwent HoLEP (study group). Patients in chronological order who underwent HoLEP without prior TURP were included in the control group. We hypothesized that prior TURP would increase technical difficulties, thereby leading to a reduction in procedure efficiency by 25%. Patients’ demographic, intraoperative, and postoperative data were compared, and statistical analysis was performed.

Results: Demographic data in both groups were comparable. The average interval between past TURP and HoLEP was 4.22 years. There was no difficulty in identifying the dissection plane in the study group and the difference in the procedure efficiency between the study and the control groups were statistically insignificant (0.75 ± 0.31 g/min-study group vs. 0.69 ± 0.36 g/min-control group; P = 0.665). The intraoperative parameters and postoperative outcomes were comparable in both groups.

Conclusions: Prior TURP does not negatively impact the outcome of HoLEP in treating symptomatic recurrence for enlarged prostate after initial TURP.

Keywords: Complication, enucleation, hematuria, holmium laser enucleation, prostatectomy, transurethral resection of prostate

INTRODUCTION

Holmium laser enucleation of prostate (HoLEP) is now considered a size-independent treatment option to treat patients with BPH. HoLEP is effective and less morbid when compared with transurethral resection of prostate (TURP) or open prostatectomy.\(^1,2\) It is
Khater, et al.: HoLEP for post-TURP recurrent BPH symptoms

also a preferred option in patients who have associated cardiopulmonary comorbidities or on anticoagulants,\[\text{8}\] and the benefits include maximum volume reduction and increased durability. Although prior TURP is presumed to increase technical difficulties in HoLEP, the outcome benefits are consistent.\[\text{4,5}\] There is limited information on the outcomes of HoLEP for recurrent symptoms due to enlarged prostate after prior TURP. All four published series that presented outcomes of HoLEP as a secondary or salvage procedure, are retrospective in nature and included patients who failed all prior interventions for BPH, including TURP.\[\text{6-9}\] Hence, it is difficult to differentiate the impact of prior TURP alone on HoLEP outcomes. The primary outcome of our study was to prospectively evaluate technical difficulties during surgery that occur due to prior TURP. We used procedure efficiency as surrogate marker of technical difficulties. The secondary outcome was to evaluate the safety and efficacy of HoLEP in patients with recurrent symptoms secondary to enlarged prostate after prior TURP by looking into the functional outcomes and complications.

MATERIALS AND METHODS

Patients
All patients who underwent HoLEP by a single surgeon (SHN) for recurrent symptoms secondary to enlarged prostate after initial TURP, at R. G. Stone Urological and Laparoscopy Hospital, S. L. Raheja (Fortis Associate) Hospital and Criticare Superspeciality hospital, Mumbai, India, from June 2003 to May 2016 were prospectively enrolled in the study. All patients in the study arm had their prior TURP done at an outside institution. This study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The clinical study was exempt from our institutional IRB as HoLEP was accepted as a standard surgical procedure for treating BPH and patients were not randomized. All patients provided informed consent. In 2003, our overall HoLEP procedure efficiency was 0.41 g/min.\[\text{10}\] It was our hypothesis that prior TURP will increase technical difficulties during surgery, leading to reduction in procedure efficiency by 25%. To show a 25% difference in HoLEP efficiency, a sample size of 45 individuals per treatment arm was required (alpha = 0.05; beta = 0.80). All patients who underwent HoLEP with a past history of TURP were consented for the procedure. These patients were included in the study group. Each patient who underwent HoLEP without prior history of TURP was included individually into the control group, immediately following the treatment patient, in that chronological order. It was our impression that this would serve as pseudo-randomization and thereby minimize selection bias.

Preoperative evaluation
All patients were evaluated with a detailed history, American Urological Association (AUA) symptom score, physical examination, serum prostate-specific antigen measurement (PSA), pelvic ultrasound, uroflowmetry, and postvoid urine volume estimation. Ascending urethrogram and micturating cystourethrography were also performed in all patients with the past history of TURP to rule out urethral stricture or bladder neck stenosis. Patients presenting with recurrent hematuria underwent contrast computerized tomography scan, urine cytology, and diagnostic cystoscopy. After confirmation of the prostatic origin of hematuria, patients who were not on finasteride therapy were started on it. Transrectal ultrasound-guided prostate biopsy was performed in patients with either raised PSA and/or abnormal digital rectal examination findings after shared decision-making. Patients who were diagnosed with urethral stricture, bladder neck stenosis, prostate cancer, or having associated neurogenic bladder were excluded from the study group. Patients with large bladder diverticula were treated with simultaneous laparoscopic diverticulectomy and excluded from this study.

Procedure
All HoLEP’s were performed using a 100W holmium laser with a 550 \(\mu\) end firing laser fiber (Lumenis, Israel). Initially, we employed a two-lobe or three-lobe technique and used laser settings of 2J and 40 Hz as described earlier.\[\text{1}\] However, from 2014, we performed our HoLEP’s at 2J and 25–30 W settings and also gradually transitioned to the En-bloc technique. The technique needed modification based on the morphology of prostate regrowth [Figure 1].

Figure 1: Cystoscopy appearance of post-TURP recurrent or residual prostate after prior TURP. TURP: Transurethral resection of prostate
Patients who had only apical tissue or only one lateral lobe or an anterior lobe, as shown in Figure 1 underwent initial enucleation of that lobe. The rest of the prostatic fossa was then evaluated for any residual adenoma for further removal. Transurethral morcellation of enucleated adenoma was performed using a Versa Cut morcellator™, which was introduced through an offset rigid nephroscope. Two patients in each group with associated calculi were treated synchronously with holmium laser cystolitholapaxy before HoLEP and the time duration of cystolitholapaxy was excluded from the calculation of procedure efficiency. At the end of the procedure, no traction was placed on the Foley catheter; however, all patients received overnight slow continuous bladder irrigation.

**Postoperative management and follow-up**

The urethral catheter was usually removed on the 1st postoperative day if urine remained clear. Patients were observed for one more night in the hospital and discharged on the 2nd postoperative day. The protocol for management after HoLEP did not change in patients with coagulopathy. Patients were restarted on antiplatelet medications 2–3 days after surgery. Immediate complications, if any, were recorded. Patients were followed up at 1-month, 6 months, and yearly thereafter. Follow-up evaluation included AUA symptoms score (AUA-SS) assessment, uroflowmetry, and sonographic estimation of postvoid residual urine. All patients were asked about any involuntary leakage of urine during each follow-up visit. We did not quantify amount of incontinence.

**Statistical analysis**

For patients in the study group, the time interval between previous TURP and HoLEP was noted. HoLEP efficiency was considered a surrogate marker for the measure of difficulty during enucleation and morcellation and was calculated by dividing resected prostate weight by the operation time (from the insertion of cystoscope to placement of Foley catheter) in g/min. It was our assumption that morcellation time would be unchanged due to prior TURP, and hence, we did not separately record enucleation and morcellation time. Demographic, perioperative, and postoperative follow-up data were compared among both group and statistical analysis was performed with IBM SPSS Statistics-24 software. Descriptive statistics were reported in number or means (± standard deviation) for categorical and continuous variables, respectively. It is well established that two times standard deviation usually provides the range which is the same as 95% of the observation. The outcome between the two groups was compared using independent sample t-test (2-tailed) for quantitative variables and Chi-squared test for qualitative data. P < 0.05 was considered statistically significant. We performed the interim analysis in October 2016 and noted that it was futile to continue the study and ended enrollment with 43 patients in each arm. We did not perform multivariate analysis as we wanted to report data in the raw state as performing multivariable analysis could potentially risk performing an under-adjustment.

**RESULTS**

During the study period, 1292 patients underwent HoLEP, of which 58 patients had a history of TURP. Among those patients with prior TURP, three patients were diagnosed to have prostate cancer before HoLEP and opted for active surveillance. Twelve patients had concurrent sub-mental stenosis and/or urethral stricture needing internal urethrotomy along with HoLEP for recurrent BPH. After excluding these 15 patients, the data of the remaining 43 patients were included in the study group.

The control group consisted of 43 patients who underwent HoLEP without a history of TURP. The average interval between TURP and HoLEP in the study group patients was 4.22 years (range 1 month – 16 years).

The demographic data in both groups were comparable except indication for surgery [Table 1]. The data of post-TURP patients were after initial TURP when they presented for HoLEP. The mean prostate size of 72.34 ± 38.22 cc in the study group was after prior TURP and before they underwent HoLEP. Gross hematuria was seen in 58.13% of patients in the study group as compared with 4.6% in the control group. The primary endpoint of procedure efficiency in the study group was 0.75 ± 0.31 g/min and in the control group was 0.69 ± 0.36 g/min. The difference in the procedure efficiency between the study and control groups was statistically insignificant (P = 0.665). The mean weight of the resected prostatic tissue was 48.38 g and 51.73 g in the study and control group, respectively (P = 0.612). Capsular perforation occurred in two patients in the study group and in three patients in the control group and the difference was not significant. This did not have any impact on the postoperative management of patients. No cases were aborted or converted to TURP form either group. Incidental prostate cancer was detected in 9.3% of patients in the study group and 13.9% in the control group. Morcellation does not impact the ability of pathologists to detect incidental prostate cancer.[11] During the follow-up period up to 12 months, there was no difference between the two groups in AUA-SSs, Qmax, and PVR [Table 2]. Postoperative complications, organized by Clavien-Dindo classification, were
comparable in both groups. Transient incontinence was seen in 9 patients in patients who had prior TURP and in 6 patients in patients who underwent initial HoLEP [Table 2]. All except 1 patient in the study group were continent at 6-month follow-up period. None of the patients had incontinence at 1-year follow-up.

**DISCUSSION**

HoLEP in patients with symptomatic BPH regardless of the size of the prostate has been confirmed by multiple randomized control trials.[12-14] However, many of these studies excluded patients with prior prostate surgery, including TURP presumably due to perceived technical difficulties that might arise secondary to earlier surgical intervention.[15-17] The first randomized trial comparing TURP with HoLEP noted that at 7-year follow-up, none of the patients initially enrolled for HoLEP required surgery for prostate regrowth. On the contrary, 3 patients initially assigned to the TURP arm had prostate regrowth and all were safely treated by HoLEP.[18]

In our institution, patients with the previous history of TURP were offered benefits of HoLEP. We considered measuring HoLEP procedure efficiency as a marker for technical difficulty during HoLEP. When we started the study in 2003, our HoLEP procedure efficiency was 0.41 g/min.[19] However, over the study period, our technique was refined and with increasing experience, our efficiency improved.

Our initial hypothesis, that adhesions and fibrosis in the plane of enucleation would make these patients more prone to intraoperative capsular perforation, was not supported by our findings. We did not find any technical difficulty in performing HoLEP in patients with prior history of TURP. There was no difficulty in identifying the enucleation plane and there was no significant difference in the procedure efficiency between the patients who had TURP before HoLEP and the patients who had HoLEP as initial prostate surgery. Due to the lack of significant differences in the primary endpoint, our hypothesis was rejected. Our findings are comparable to other retrospective studies published in the literature [Table 3].[6-9] Capsular perforation was noted in 5 patients, 2 in the study group and 3 in the control group and the difference was statistically insignificant. We noted that prior TURP did not cause significant adhesions between the residual adenoma and the surgical capsule. While we did note more bladder neck fibrosis, this did not impact outcomes. Similar findings were noted by Jaeger et al. while evaluating the outcome of HoLEP in 37 patients with prior prostate surgery, of which 16 patients had previous TURP.[8] Elshal et al. noted that increased need for sharp dissection with laser after prior prostate surgeries, thereby increasing energy utilization in patient undergoing a secondary HoLEP (226.7 vs. 186.3 KJ).[7] Contradicting our experience and those of others, Oh et al. noted that 3/35 patients undergoing salvage HoLEP after prior prostate surgeries that included TURP, photo-selective vaporization of prostate and transurethral needle ablation of prostate had ill-defined
and nonprominent plane for enucleation.\(^8\) They did not specify which prostate surgery these patients had before HoLEP as their study group included patients with varieties of previous prostate surgeries, including TURP.

We did not notice any significant difference in the postoperative complications and outcome amongst both groups of patients. These findings were comparable to other published retrospective series in the literature.\(^6\)\(-8\)

Contradictory to our results, the largest multi-centric retrospective study from 4 tertiary referral centers in the United States evaluating outcomes of 360 patients who underwent salvage HoLEP after varieties of initial BPH procedures noted that salvage HoLEP was associated with marginal increase in risk of clot retention and urethral stricture at 6 months follow-up.\(^9\) Despite these marginal differences, the outcome was favorable and comparable to patients undergoing HoLEP as the primary procedure to treat BPH in this study. In our study, the technique of HoLEP changed over time. Although various surgical techniques result in similar outcomes, their impact on the duration of surgery is controversial. Rucker et al. noted that en-bloc and two-lobe enucleation were significantly faster with respect to enucleation time as compared to the three-lobe technique.\(^19\) However, Enikeev et al. noted no such difference in the duration of surgery.\(^20\)

We also noted gross hematuria to be the most common indication of surgical intervention in study group patients (58.13% in the study group vs. 4.6% in the control group).

### Table 2: Patient’s intraoperative parameters and postoperative outcomes

| Parameters                                      | Study group (prior TURP) | Control group (no prior TURP) | P     |
|-------------------------------------------------|--------------------------|-------------------------------|-------|
| Duration of surgery (min)                       | 63.35±20.35              | 74.91±31.64                   | 0.472 |
| Postoperative catheterization (h)               | 35.00±5.84               | 36.49±5.58                    | 0.231 |
| Hospital stay (h)                               | 39.19±5.48               | 40.30±5.80                    | 0.326 |
| Resected prostate weight (g)                    | 48.38±30.42              | 51.73±28.21                   | 0.612 |
| HoLEP efficiency (g/min)                        | 0.75±0.31                | 0.69±0.36                     | 0.665 |
| Hemoglobin drop (g/dl)                          | 0.76±0.38                | 0.70±0.43                     | 0.484 |
| 1-month AUA symptom score (AUA-SS)              | 6.37±2.64                | 6.45±2.86                     | 0.901 |
| 1-month Omax (ml/min)                           | 28.80±11.09              | 27.17±11.39                   | 0.590 |
| 1-month PVR (ml)                                | 32.58±36.81              | 29.09±32.08                   | 0.697 |
| 3-month AUA-SS                                  | 5.0±2.17                 | 4.9±2.34                      | 0.914 |
| 3-month Omax (ml/min)                           | 24.96±7.63               | 21.4±7.00                     | 0.840 |
| 3-month PVR (ml)                                | 21.64±26.19              | 20.5±15.44                    | 0.832 |
| 6-month AUA-SS                                  | 4.83±1.92                | 4.5±2.00                      | 0.578 |
| 6-month Omax (ml/min)                           | 22.48±7.34               | 22.20±7.10                    | 0.889 |
| 6-month PVR (ml)                                | 24.89±26.66              | 22.93±26.01                   | 0.781 |
| 1-year AUA-SS                                   | 4.90±1.85                | 4.74±2.08                     | 0.769 |
| 1-year Omax (ml/min)                            | 22.34±6.94               | 22.09±6.18                    | 0.893 |
| 1-year PVR (ml)                                 | 21.81±17.48              | 19.5±19.91                    | 0.665 |

| Complications*                                   | Number (percentage)      | Number (percentage)          | P     |
|-------------------------------------------------|--------------------------|-------------------------------|-------|
| Intraoperative complications                     |                          |                               | 0.775 |
| Bleeding                                        | 1 (2.3)                  | 2 (4.6)                       |       |
| Capsular perforation                            | 2 (4.6)                  | 3 (6.9)                       |       |
| Superficial mucosal injury                       | 3 (6.9)                  | 2 (4.6)                       |       |
| Superficial ureteric orifice injury              | 0                        | 1 (2.3)                       |       |
| Intraoperative blood transfusion                 | 0                        | 1 (2.3)                       |       |
| Postoperative complications                     |                          |                               |       |
| Clavien-dindo I                                  |                          |                               |       |
| Urine incontinence                               | 9 (20.9)                 | 6 (13.9)                      | 0.798 |
| At 6 months                                     | 1 (2.3)                  | 0                             |       |
| At 1 year                                       | 0                        | 0                             |       |
| Clavien-dindo II                                 |                          |                               |       |
| Blood transfusion                                | 1 (2.3)                  | 0                             |       |
| Urinary tract infection                          | 3 (6.9)                  | 3 (6.9)                       |       |
| Epididymitis                                     | 1 (2.3)                  | 0                             |       |
| Clavien-dindo IIIa                               |                          |                               |       |
| Recatheterization                               | 1 (2.3)                  | 0                             |       |
| Clavien-dindo IIIb                               |                          |                               |       |
| Meatal/sub-meatal stenosis                       | 0                        | 1 (2.3)                       |       |
| Bulbar urethral stricture                        | 1 (2.3)                  | 0                             |       |
| Bladder neck contracture                         | 0                        | 1 (2.3)                       |       |
| Incidental adenocarcinoma prostate               | 4 (9.3)                  | 6 (13.9)                      | 0.797 |

SD: Standard deviation, AUA: American Urological Association, TURP: Transurethral resection of prostate, HoLEP: Holmium laser enucleation of prostate, SS: Symptom score, PVR: Post void residual urine.
group). Similar to our findings, Bowden et al. analyzed 100 patients with gross hematuria and a history of TURP and noted that 63% of patients had prostatic regrowth responsible for bleeding. Based on their findings, they considered hematuria as a late complication of TURP.[21] Similarly, Wang et al. noted that the primary reason for admission in patients with recurrent BPH (post-TURP) was severe hematuria (44.4%).[22] On pathologic evaluation, post-TURP recurrent prostate tissue was more irregular and friable. The tissue also had a higher microvessel density with thinner blood vessels, making them more likely to bleed. Other authors who evaluated the efficacy of salvage HoLEP did not find a high incidence of recurrent hematuria in their patients.[7,9] This might be attributable to the inclusion of patients with prostatic intervention other than TURP in their series.

One of the limitations of our study is that it describes a single surgeon's experience with prostate sizes averaging <80 g. Therefore, our results might not be relevant to HoLEP's performed for larger prostate sizes. Another limitation is that the enrollment period for this prospective study was 13 years, since we strictly included only patients with prior TURP, as opposed to other prior BPH interventions. Even so, our study stands out since all four previously published series that presented outcomes of HoLEP as a secondary or salvage procedure are retrospective in nature and included patients who failed not just TURP but a variety of different prior interventions for BPH.[6-9] This makes it difficult to differentiate the impact of prior TURP on HoLEP outcomes based on those earlier published studies alone. We also believe that early symptoms after TURP can also be attributable to incomplete adenomectomy for larger prostates done at outside institutions. It is possible that our ability to find and maintain the plane of enucleation might be attributable to nonviolation of the capsule resulting from incomplete resection in some patients. We did not perform subgroup analysis of the impact of time interval from the previous TURP on the duration of surgery. It would be interesting to perform subgroup analysis of the impact of time interval from initial TURP on the difficulty of enucleation and incidence of postoperative transient urine incontinence. Finally, our study lacks long-term data. However, the long-term durability of HoLEP is well established. Despite these limitations, our study is the first and only prospective study confirming safety and efficacy of HoLEP in treating patients with recurrent symptoms due to enlarged prostate after prior TURP.

CONCLUSIONS

Our study reveals that prior TURP does not negatively impact the outcome of HoLEP in treating recurrent symptoms due to enlarged prostate.

Financial support and sponsorship
Nil.

Conflicts of interest
Dr. Hemendra N. Shah served as trainer for HoLEP for LUMENIS and received 1000$ remuneration in 2018. All other authors have no disclosures or conflicts of interest.

REFERENCES

1. Tan A, Liao C, Mo Z, Cao Y. Metaanalysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 2007;94:1201-8.
2. Lourenco T, Pickard R, Vale I, Grant A, Fraser C, MacLennan G, et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: Systematic review of randomised controlled trials. BMJ 2008;337:a449.
3. Rivera M, Krambeck A, Lingeman J. Holmium laser enucleation of
the prostate in patients requiring anticoagulation. Curr Urol Rep 2017;18:77.
4. Kuntz RM, Ahyai S, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral resection of the prostate: A randomized prospective trial in 200 patients. J Urol 2004;172:1012-6.
5. Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 2010;183:1105-9.
6. Jaeger CD, Krambeck AE. Holmium laser enucleation of the prostate for persistent lower urinary tract symptoms after prior benign prostatic hyperplasia surgery. Urology 2013;81:1025-9.
7. Elshal AM, Elmansy HM, Elhilali M. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH). Br J Urol Int 2012;110:E845-50.
8. Oh JK, Bae J, Jeong CW, Paick JS, Oh SJ. Salvage Holmium laser enucleation of prostate to treat residual benign prostatic hyperplasia. Can Urol Assoc J 2014;8:E235-40.
9. Marien T, Kadihasanoglu M, Tangpaitoon T, York N, Blackburne AT, Abdul-Muhsin H, et al. Outcomes of holmium laser enucleation of the prostate in the re-treatment setting. J Urol 2017;197:1517-22.
10. Shah HN, Mahajan AP, Sodha HS, Hegde S, Mohile PD, Bansal MB. Prospective evaluation of the learning curve for holmium laser enucleation of the prostate. J Urol 2007;177:1468-74.
11. Nastro R, Freschi M, Salonia A, Guazzoni G, Girolamo V, Colombo R, et al. Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 2004;171:1203-6.
12. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): Long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol 2007;52:1465-71.
13. Yin L, Teng J, Huang C, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: A systemic review and meta-analysis of randomized controlled trials. J Endourol 2013;27:604-11.
14. Shah HN, Sodha H, Kharodawala S, Khandkar A, Hegde SS, Bansal MB. Influence of prostate size on outcome of holmium laser enucleation of prostate (HoLEP). BJU Int 2008;101:1536.
15. Wilson LC, Gilling PJ, William A, Kennett KM, Frampton CM, Westenberg AM, et al. A randomized trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: Result at 2 years. Eur Urol 2006;50:569-73.
16. Fayad AS, Sheikh MG, Zakaria T, Elfottoh HA, Alsergany R. Holmium laser enucleation versus bipolar resection of the prostate: A prospective randomized study. Which to choose? J Endourol 2011;25:1347-52.
17. Eltabey MA, Sherif H, Hussein AA. Holmium laser enucleation versus transurethral resection of the prostate. Can J Urol 2010;17:5447-52.
18. Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: Results at 7 years. BJU Int 2012;109:408-11.
19. Rücker F, Lehrich K, Böhme A, Zacharias M, Ahyai SA, Hansen J. A call for HoLEP: En-bloc vs. two-lobe vs. three-lobe. World J Urol 2021;39:2337-45.
20. Enikeev D, Taratkin M, Laktuhtina E, Alekseeva T, Snurnitsyna O, Potolskova N, et al. En bloc and two-lobe techniques for laser endoscopic enucleation of the prostate: Retrospective comparative analysis of peri- and postoperative outcomes. Int Urol Nephrol 2019;51:1969-74.
21. Bowden EA, Foley SJ. Haematuria; a late complication of TURP? Prostate Cancer Prostatic Dis 2001;4:178-9.
22. Wang X, Lu Zhu X, Bai PM, Luo GC. Severe hematuria in recurrent benign prostatic hyperplasia: Underlying pathology. Clin Surg 2020;5:2763.